Literature DB >> 20406100

The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese.

Yan He1, Jianqiang Ni, Shougong Chen, Yuting Jiang, Shasha Jia, Yuzhen Gao.   

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis, which is crucial for development and metastasis of tumors including hepatocellular carcinoma (HCC), and elevated VEGF levels in serum and tissues have been known to be related with poor prognosis in patients with HCC. Polymorphisms in VEGF may alter VEGF protein concentrations, influence the process of angiogenesis, and may relate to interindividual variation in tumorigenesis. In this study, we carried out a case-control study in a Chinese population (206 cases and 302 controls) to estimate the susceptibility to HCC associated with an 18-bp insertion/deletion polymorphism (rs35569394) in the promoter region of VEGF. After adjusting the data by gender, age, smoking status, drinking status, and hepatitis B virus (HBV) infection using logistic regression model, we found that rs35569394 was not associated with HCC, at both the allele and genotype levels. Thus, rs35569394 should not be viewed as a major contributor to the development of HCC in Chinese.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406100     DOI: 10.1089/dna.2009.1015

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  8 in total

1.  The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population.

Authors:  Yiqi Jin; Qiang Yu; Dayong Zhou; Lei Chen; Xianchen Huang; Guoxiong Xu; Jian Huang; Xueren Gao; Yuzhen Gao; Liming Shen
Journal:  Genet Test Mol Biomarkers       Date:  2012-01-27

2.  A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population.

Authors:  Lingling Jiang; Jingya Xu; Jianqiang Ni; Xueren Gao; Zhansheng Zhu; Dong Dong; Xiaoshu Wang; Chunhua Shi; Xiaoyang Tao; Wanli Dong; Yuzhen Gao
Journal:  DNA Cell Biol       Date:  2012-06-25       Impact factor: 3.311

3.  Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians.

Authors:  Ruhi Kapahi; Kamlesh Guleria; Vasudha Sambyal; Mridu Manjari; Meena Sudan; Manjit Singh Uppal; Neeti Rajan Singh
Journal:  Tumour Biol       Date:  2015-01-22

4.  Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study.

Authors:  Kamlesh Guleria; Simranjot Kaur; Deepanshi Mahajan; Vasudha Sambyal; Meena Sudan; Manjit Singh Uppal
Journal:  Genes Genomics       Date:  2022-06-29       Impact factor: 2.164

5.  Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in North Indian patients.

Authors:  Ruhi Kapahi; Mridu Manjari; Manjit Singh Uppal; Neeti Rajan Singh; Vasudha Sambyal; Kamlesh Guleria
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-07

6.  VEGF Promoter Region 18-bp Insertion-Deletion Polymorphism in Sickle Cell Disease Patients with Microalbuminuria: A Pilot Study.

Authors:  Dnyanesh B Amle; Rachana L Patnayak; Varsha Verma; Gajendra Kumar Singh; Vijaylakshmi Jain; P K Khodiar; P K Patra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-08       Impact factor: 0.900

7.  Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.

Authors:  Fei Liu; Limei Luo; Yonggang Wei; Wentao Wang; Tianfu Wen; Jiayin Yang; Mingqing Xu; Bo Li
Journal:  Oncotarget       Date:  2017-03-07

8.  The Association Analysis of Vascular Endothelial Growth Factor -2549 Insertion/ Deletion Variant and Endometriosis Risk.

Authors:  Negar Sarhangi; Shahrzad Mohseni; Soheila Aminimoghaddam; Batool Hossein Rashidi; Fedyeh Haghollahi; Mostafa Qorbani; Mahsa Mohammad Amoli; Maryam Shahrabi-Farahani
Journal:  Int J Mol Cell Med       Date:  2019-05-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.